Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Enzyme Therapy For Fabry Disease: Neutralizing Antibodies Toward Agalsidase Alpha And Beta.

G. Linthorst, C. Hollak, W. Donker-Koopman, A. Strijland, J. M. F. Aerts
Published 2004 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of alpha-Gal A antibodies in treated patients. METHODS During the first 6 to 12 months of intravenous administration of recombinant enzymes (rh-alpha-Gal A) formation of antibodies was studied in 18 adult Fabry patients (two females). RESULTS The female patients did not develop detectable amounts of antibodies following enzyme therapy. After 6 months of treatment with either agalsidase alpha or beta, 11/16 male patients showed high titers of immunoglobulin G (IgG) antibodies that cross-react in vitro similarly with both recombinant enzymes. The anti-rh-alpha-Gal A IgG neutralizes rh-alpha-Gal A activity in vitro for 65% to 95%. During infusion with rh-alpha-Gal A, circulating enzyme-antibody complexes are formed and these complexes are taken up by leukocytes in the peripheral blood. After 6 months of treatment all IgG-negative patients showed a significant (P < 0.01) reduction of urinary CTH (1890 +/- 797 to 603 +/- 291 nmol CTH/24hr urine), compared to IgG-positive patients (mean increase from 2535 +/- 988 to 2723 +/- 1212), suggesting a negative effect of circulating antibodies on renal tubular CTH clearance. CONCLUSION Emergence of antibodies with in vivo neutralizing capacities is frequently encountered in treated Fabry disease patients. Complete cross-reactivity of these antibodies suggests that it is unlikely that switching from one to the other recombinant protein prevents the immune response and related effects. Further studies on the clinical implications of alpha-Gal A antibodies are essential.
This paper references
10.1542/PEDS.100.6.E11
Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.
R. Brady (1997)
10.1056/NEJMOA011931
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
N. Casadevall (2002)
10.1016/0009-8981(81)90384-3
Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease.
J. Mayes (1981)
10.1056/NEJM199105233242104
Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
N. Barton (1991)
10.1086/345309
Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA
D. Blom (2003)
10.1182/BLOOD.V93.6.2081.406K07_2081_2088
Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.
M. Rosenberg (1999)
A simple method for the isolation and purification of total lipids from animal tissues
Jordi Folch (1957)
10.1016/s0021-9258(18)64849-5
A simple method for the isolation and purification of total lipides from animal tissues.
J. Folch (1957)
10.1056/NEJM200101183440304
Enzyme-replacement therapy in mucopolysaccharidosis I.
E. Kakkis (2001)
10.1001/JAMA.285.21.2743
Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
R. Schiffmann (2001)
10.1111/j.1365-2362.2004.01309.x
Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey
A. Mehta (2004)
α-Galactosidase A deficiency. Fabry disease
R. Desnick (2001)
10.1056/NEJM200107053450102
Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
C. Eng (2001)
10.1016/S0140-6736(01)05816-0
Enzyme-replacement therapy for Anderson-Fabry disease
G. Pastores (2001)
10.1046/J.1523-1755.2002.00675.X
Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.
B. Thurberg (2002)
10.1056/NEJM199302183280701
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
J. Lusher (1993)
10.1517/13543784.11.6.851
Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease
M. Beck (2002)
10.1016/J.MOLMED.2003.08.004
Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
D. Brooks (2003)
10.1016/S0140-6736(00)02533-2
Recombinant human α-glucosidase from rabbit milk in Pompe patients
H. V. D. Hout (2000)



This paper is referenced by
10.1007/s10545-011-9308-6
Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies
J. Aerts (2011)
10.1016/j.ymgme.2017.05.001
Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
M. Arends (2017)
10.1136/jmedgenet-2017-104863
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
M. Arends (2018)
10.3389/fpls.2017.01026
Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry Disease
K. Kytidou (2017)
10.1681/ASN.2018070740
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
M. Lenders (2018)
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL FACULDADE DE MEDICINA PROGRAMA DE PÓS-GRADUAÇÃO EM MEDICINA: CIÊNCIAS MÉDICAS
Patologia Molecular (2003)
10.1007/8904_2015_422
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
O. Goker-Alpan (2015)
10.1016/J.YMGME.2007.06.013
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
T. Ohashi (2007)
10.7326/0003-4819-146-2-200701160-00147
Enzyme Replacement in Fabry Disease: The Essence Is in the Kidney
R. Schiffmann (2007)
10.1007/8904_2014_371
Innate and Adaptive Immune Response in Fabry Disease.
W. Mauhin (2015)
10.1007/978-90-481-9033-1_7
Biomarkers for Fabry Disease
J. Aerts (2010)
10.1016/J.PROCBIO.2008.11.009
Biochemical and hydrolytic properties of multiple thermostable α-galactosidases from Streptomyces griseoloalbus: Obvious existence of a novel galactose-tolerant enzyme
G. S. Anisha (2009)
10.1186/s13023-020-01582-7
The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
Markus S. Mueller (2020)
10.1142/9789814271325_0006
Current and Emerging Therapies
G. Pastores (2009)
10.1111/joim.12089
Fabry disease: is there a role for enzyme replacement therapy?
A. Mehta (2013)
10.1111/j.1742-1241.2006.01237.x
Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature
O. Lidove (2007)
10.1201/B15274-20
Therapy for Neuronopathic Lysosomal Storage Diseases
Ayaz Khawaja (2013)
10.1016/j.jjcc.2010.08.003
Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
Chyan-Jang Lee (2011)
10.1007/8904_2012_160
Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.
G. Linthorst (2013)
10.1002/cmdc.201800094
Antibody Epitope of Human α‐Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease
Z. Kukačka (2018)
10.1016/J.PROCBIO.2006.01.003
Purification, characterization and substrate specificity of thermostable α-galactosidase from Bacillus stearothermophilus (NCIM-5146)
M. Gote (2006)
10.1016/j.bbadis.2010.09.007
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
Mariëlle J. van Breemen (2011)
10.1586/17446651.2.2.147
Agalsidase alfa therapy for Fabry disease
S. Sirrs (2007)
Screening for Fabry disease: indications, methods and implications
Wim Terryn (2013)
10.5772/24366
Nanomedicine and Drug Delivery Strategies for Treatment of Genetic Diseases
J. Hsu (2011)
10.1016/S0248-8663(10)70012-6
[Third French multidisciplinary meeting on Fabry disease].
Dominique P Germain (2010)
10.1177/08830738050200031101
New Treatments for Denervating Diseases
David Pleasure (2005)
10.1016/j.ymgmr.2014.07.001
Frequency of de novo mutations in Japanese patients with Fabry disease
M. Kobayashi (2014)
10.1542/peds.2005-2895
Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease
M. Ries (2006)
10.1517/13543784.2010.524205
Pharmacological small molecules for the treatment of lysosomal storage disorders
B. E. Smid (2010)
10.1007/s00253-016-7689-z
α-Galactosidase delivery using 30Kc19-human serum albumin nanoparticles for effective treatment of Fabry disease
Hong Jai Lee (2016)
10.1093/NDT/GFI221
Home treatment for Fabry disease: practice guidelines based on 3 years experience in The Netherlands.
G. Linthorst (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar